

IX BIOPHARMA LTD
(Incorporated in Singapore)
(Company Registration No. 200405621W)

PROPOSED DEBT CAPITALISATION - COMPLETION OF ISSUANCE AND ALLOTMENT

*Unless otherwise defined, all capitalised terms used herein shall have the same meanings as ascribed to them in the announcements of the Company dated 5 October 2026 and 8 October 2026 in relation to the Proposed Debt Capitalisation (collectively, the “**Previous Announcements**”).*

The Board of Directors of iX Biopharma Ltd. (the “**Company**”) (the “**Board**” or the “**Directors**”) refers to the Previous Announcements.

The Board wishes to announce that the Company has, on 9 October 2026, completed the issuance and allotment of 2,682,779 Capitalisation Shares pursuant to the Proposed Debt Capitalisation at the Issue Price of S\$0.5627 per Capitalisation Share, in full and final settlement of the Capitalised Debt of A\$1,700,000 (equivalent to S\$1,509,600) (the “**Completion**”).

Following Completion, the issued and paid-up share capital of the Company has increased from 1,093,315,474 shares to 1,095,998,253 shares. The Capitalisation Shares represent approximately 0.24% of the enlarged issued and paid-up share capital of the Company.

The Capitalisation Shares rank *pari passu* in all respects with the existing shares of the Company, save that they will not rank for any dividend, right, allotment or other distributions, the record date for which falls on or before the Completion Date, and are expected to be listed and quoted on the Catalist Board of the Singapore Exchange Securities Trading Limited on or around 13 October 2026. With the allotment and issuance of the Capitalisation Shares, the Capitalised Debt is deemed fully repaid and discharged.

By Order Of The Board
IX BIOPHARMA LTD.

Gwendolin Lee Soo Fern
Company Secretary

9 October 2026

*This announcement has been reviewed by the Company’s Sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the*

contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01, UE Square, Singapore 239920, telephone: (65) 6590 6881.